Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO-B

408.600
-7.400-1.78%
Volume:300.82K
Turnover:120.97M
Market Cap:95.28B
PE:-339.49
High:416.000
Open:416.000
Low:396.200
Close:416.000
52wk High:581.000
52wk Low:198.000
Shares:233.19M
HK Float Shares:162.77M
Volume Ratio:1.43
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.204
ROE:-17.56%
ROA:-9.92%
PB:16.73
PE(LYR):-339.49
PS:55.91

Loading ...

BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts

Reuters
·
Feb 19

SKB BIO-B Falls 3.33% Against Market Trend, Weighed by Sector Weakness and Divergent Institutional Views

Deep News
·
Feb 12

China International Capital Maintains Outperform Rating on SKB BIO-B (06990) with HK$550 Target Price

Stock News
·
Feb 11

Goldman Sachs: Mainland Healthcare Sector Returns to Hinge on Data and Earnings Visibility This Year, CDMO Firms Favored

Stock News
·
Feb 09

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Trop2 Adc Sacituzumab Tirumotecan Approved For Marketing For Fourth Indication By China's NMPA

Reuters
·
Feb 06

Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (Sac-TMT) Approved by Nmpa in Hr+/Her2- Breast Cancer

THOMSON REUTERS
·
Feb 06

Sichuan Kelun-Biotech (6990) Announces Fourth NMPA Approval of TROP2 ADC Sacituzumab Tirumotecan for Advanced HR+/HER2- Breast Cancer

Bulletin Express
·
Feb 06

SKB BIO-B's Core TROP2 ADC Therapy Sac-TMT Gains Fourth Indication Approval in China for HR+/HER2- Breast Cancer

Stock News
·
Feb 06

Sichuan Kelun-Biotech Biopharmaceutical - Trop2 ADC Sacituzumab Tirumotecan Approved for Marketing for Fourth Indication by Nmpa

THOMSON REUTERS
·
Feb 06

Sichuan Kelun-Biotech Receives NMPA Approval for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer

Reuters
·
Feb 06

Kelun-Biotech (06990) Releases January 2026 Monthly Return

Bulletin Express
·
Feb 04

Sichuan Kelun-Biotech Renews R&D Procurement Deal With China Resources Kelun; Shares Slip 5%

MT Newswires Live
·
Jan 19

Does Breakthrough Status For Sacituzumab Tirumotecan-Keytruda Combo Reshape Kelun-Biotech’s Oncology Strategy (SEHK:6990)?

Simply Wall St.
·
Jan 17

Kelun-Biotech Releases Latest Corporate Presentation Document

Reuters
·
Jan 16

Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up

Simply Wall St.
·
Jan 10

Kelun-Bota Biotech-B (06990) Terminates Subscription of 980 Million Yuan Bank of China Structured Deposit

Stock News
·
Jan 07

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Subscription For BOC Structured Deposit II Terminated

Reuters
·
Jan 07

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Subscription for BOC Structured Deposit Ii Terminated

THOMSON REUTERS
·
Jan 07

Kelun-Biotech to Present Business Progress and Innovation Strategies at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

Kelun-Biotech to Attend the 44TH J.p. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies

THOMSON REUTERS
·
Jan 07